Cryoport, Inc. (CYRX)
After hours:
| Previous close | 13.20 |
| Open | 13.08 |
| Bid | 13.43 x 100 |
| Ask | 13.49 x 100 |
| Day's range | 12.82 - 13.54 |
| 52-week range | 9.00 - 23.50 |
| Volume | |
| Avg. volume | 476,029 |
| Market cap | 663.005M |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Cryoport Reports First Quarter 2024 Financial Results
Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024. Jerrell Shelton, CEO of Cryoport, commented, "For the first quarter, we continued to experience a difficult environment globally. Our quarterly results were disappointing, particularly for our Life Sciences Products. However, as stated when we initially provided our annual guidance, we anticipate our revenue w
- PR Newswire
Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024
Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close.
- PR Newswire
Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023. Jerrell Shelton, CEO of Cryoport, commented, "Today we reported full year results including total revenue of $233.3 million for the fiscal year ended December 31, 2023. Our results were within our revenue guidance range, despite the challenging operating environment we experienced thro
